Swiss pharma giants Roche and Novartis fight over patent in US court
Roche claims there was a patent infringement on the lung drug Esbriet.
Copyright 2016 The Associated Press. All Rights Reserved.
This content was published on
1 minute
Keystone-SDA/ds
Swiss pharmaceutical giant Roche is taking its rival Novartis to court in the US. Roche subsidiary Genentech has filed suit in New Jersey District Court against Novartis subsidiary Sandoz for patent infringement on the lung drug Esbriet.
This is according to the indictment filed on Monday, cited by the Keystone-SDA news agency. The case was first reported by Reuters.
Genentech complains that Sandoz started selling a generic version of Esbriet in mid-May 2022, even though Sandoz had not applied for a license. As a result, Genentech’s patent had been infringed, it said. The generic displacement of Esbriet has caused significant financial harm to the Roche subsidiary, it said. Esbriet had sales of more than $740 million (CHF650 million) in the U.S. alone in 2021.
Genentech is now seeking unspecified damages including lost profits and/or an appropriate royalty. Sandoz is also expected to pay the legal costs.
Genentech’s Esbriet is used to treat idiopathic pulmonary fibrosis (IPF), a fatal chronic lung disease with no cure. Roche earned over $1 billion worldwide from Esbriet in 2021, but sales fell to under $820 million in 2022, according to Reuters.
Popular Stories
More
Swiss Politics
Swiss reject plans for bigger motorways and extra rights for landlords
This content was published on
It is not necessary to define Swiss neutrality more strictly, according to the Swiss government. The Federal Council has rejected the so-called “neutrality initiative”.
Swiss government to improve disaster alert system via mobile phones
This content was published on
The Federal Council wants to modernise the disaster warning system for the population with alerts sent via the mobile phone network and other digital channels.
Poll: most Swiss believe littering is steadily decreasing
This content was published on
Littering is steadily decreasing in Switzerland, according to an annual survey conducted by the Swiss Center of Excellence against Littering.
This content was published on
The Federal Criminal Court has acquitted UBS following appeal proceedings in connection with money laundering charges linked to the Bulgarian mafia. The bank inherited the case from Credit Suisse.
This content was published on
The Swiss Federal Railways (SBB/CFF) timetable change on December 15 will bring improvements for commuters. It will also have new night-time connections on long-distance and regional services.
Swiss launch healthcare initiative to improve working conditions of doctors and nurses
This content was published on
The Swiss authorities have launched an initiative to promote healthcare centres and improve working conditions for doctors, nurses and pharmacists.
Morges fatal shooting: police officer acted in self-defence, prosecutors conclude
This content was published on
The police officer who shot dead a black man at Morges train station in western Switzerland in 2021 acted in self-defence, the Office of the Attorney General of canton Vaud have concluded.
This content was published on
Switzerland has welcomed the announcement of a ceasefire deal between Israel and the Iran-backed group Hezbollah in Lebanon.
Gender wage gap is shrinking in Switzerland – slowly
This content was published on
The gender wage gap is narrowing in Switzerland, although it remains sizeable and partly unexplained: in 2022 women earned on average 16.2% less than their male counterparts.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis seals deal to license high-priced cancer drug
This content was published on
Swiss pharma giant Novartis has finalised a deal to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
This content was published on
Switzerland takes the top spot in total patent filings per capita to the European Patent Office. Roche and ABB lead the field among Swiss companies.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.